新京报贝壳财经讯 7月15日，昨日大涨7%的昭衍新药再度涨停。消息面上，昭衍新药昨日曾公告，预计2026年上半年归母净利润为6亿—9亿元，同比增长884.9%—1377.4%。报告期内，生物资产市场价格上涨叠加自身自然生长增值，双重因素驱动其公允价值正向变动，为公司业绩做出积极贡献。据报道，昭衍新药是国内药物非临床CRO领域的龙头，拥有大量实验猴资源。（文章来源：新京报）
Source Link新京报贝壳财经讯 7月15日，昨日大涨7%的昭衍新药再度涨停。消息面上，昭衍新药昨日曾公告，预计2026年上半年归母净利润为6亿—9亿元，同比增长884.9%—1377.4%。报告期内，生物资产市场价格上涨叠加自身自然生长增值，双重因素驱动其公允价值正向变动，为公司业绩做出积极贡献。据报道，昭衍新药是国内药物非临床CRO领域的龙头，拥有大量实验猴资源。（文章来源：新京报）
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.